Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Golexanolone

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Umecrine Cognition presents results from a preclinical study of golexanolone
    Umecrine Cognition presents results from a preclinical study of golexanolone

    28 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/28/2523935/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-presents-positive-results-from-a-preclinical-study-of-golexanolone.html

    GLOBENEWSWIRE
    28 Sep 2022
    Share Share
    Karolinska Development’s portfolio company Umecrine Ph2 study of golexanolone
    Karolinska Development’s portfolio company Umecrine Ph2 study of golexanolone

    14 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/14/2515677/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-secures-funding-ahead-of-Phase-2-study-of-golexanolone-in-primary-biliary-cholangitis.html

    GLOBENEWSWIRE
    14 Sep 2022
    Share Share
    Karolinska Devp’s portfolio company Umecrine ph2a study of golexanolone
    Karolinska Devp’s portfolio company Umecrine ph2a study of golexanolone

    08 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/08/2030150/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-presents-positive-additional-results-from-a-phase-2a-study-of-golexanolone.html

    GLOBENEWSWIRE
    08 May 2020
    Share Share
    Karolinska Development’s portfolio company ph2a clinical study of golexanolone
    Karolinska Development’s portfolio company ph2a clinical study of golexanolone

    03 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/03/2011609/0/en/Karolinska-Development-s-portfolio-company-Umecrine-Cognition-announces-results-from-a-phase-2a-clinical-study-of-golexanolone.html

    GLOBENEWSWIRE
    03 Apr 2020
    Share Share